Philipp Harter

24PUBLICATIONS
153CO-AUTHORS
Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical ethicsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 12, 2026
Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

|Dec 03, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Philipp Harter, Frederik Marmé, Andrés Redondo

|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium.

Nicole Concin, Ioana Braicu, Pierre Combe

|Apr 01, 2025
Expert commentary on HORSE/MITO18 and CHIPOR.

Edin Karabeg, Philipp Harter

|Nov 04, 2024
How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.

Jalid Sehouli, Jolijn Boer, Alison H Brand

|Dec 21, 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Domenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter

Pageof 4

Frequent Collaborators

7 joint publications

Florian Heitz

7 joint publications

Jalid Sehouli

6 joint publications

Isabelle Ray-Coquard

3 joint publications

Pauline Wimberger